

## Druggable Targets in Diseases Due to Mucociliary Dysfunction and Bronchiectasis

Chiesi Farmaceutici S.p.A, one of the top 50 pharmaceutical companies in the world, is seeking **novel targets/therapeutics** for respiratory diseases with a clinical unmet need, such as chronic obstructive pulmonary disorder (COPD), non-CF bronchiectasis and mucociliary dysfunction, that have a **competitive edge on current treatments**.



### Approaches of Interest:

- Novel druggable targets and therapeutic approaches for **respiratory diseases including COPD, non-CF bronchiectasis, mucociliary dysfunction, primary ciliary dyskinesia** etc.
- Open to different modalities, including **small molecules, RNA-based or peptide-based therapeutics and antibodies**

### Out of Scope:

- Targets and therapeutic approaches for asthma and CF-related bronchiectasis
- Gene therapy and cell therapy approaches
- Opportunities related to medical devices, diagnostics and monitoring

### Development Stages of Interest:

- Opportunities from basic research to the preclinical research phase are within scope, provided that there is experimental validation of the target/therapeutic
- Opportunities with *in vivo* validation are of the highest interest, although opportunities with *in vitro* or *ex vivo* validation (e.g., airway liquid interface cultures, precision-cut lung slices etc.) will still be considered

### Submission Information:

Submission of one-page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g., relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

### Opportunity for Collaboration:

Chiesi Farmaceutici S.p.A is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. They are flexible in how they engage with academic institutions. Example outcomes include licensing assets, co-development, and research collaborations.

### Opportunities sought

- 💡 Technologies
- 🎓 Academics and expertise
- 🏆 Centres of excellence
- 🧪 Research projects
- 🏢 Spinout companies
- 🧬 Biotech assets

### Submissions

Please submit relevant, non-confidential opportunities online via: [discover.in-part.com](https://discover.in-part.com)

Deadline: **10th July 2023 - 10:59 pm GMT**

#### Have any questions?

Contact our team at [discover@in-part.co.uk](mailto:discover@in-part.co.uk)

